# Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

> **NCT00123890** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline**

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** GW873140

## Key facts

- **NCT ID:** NCT00123890
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated due to hepatoxicity of compound
- **Last updated:** 2011-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123890, "Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00123890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*